Alex G. Howarth has been the CEO of Madrigal Pharmaceuticals, Inc. since July 2016. During his time, the company has focused heavily on research and development in the fast-paced biopharmaceutical industry. Under Alex's leadership, Madrigal has achieved significant milestones, including...

Alex G. Howarth has been the CEO of Madrigal Pharmaceuticals, Inc. since July 2016. During his time, the company has focused heavily on research and development in the fast-paced biopharmaceutical industry. Under Alex's leadership, Madrigal has achieved significant milestones, including navigating complex clinical trials and securing a strong market position. In 2023, Alex received a total compensation of $1,668,000, with a significant portion of this coming from performance bonuses, reflecting his ability to drive success and reach company goals. Interestingly, Alex has been quite active in insider trading, with notable fluctuations in his company stock holdings throughout 2023. For example, at the beginning of January 2023, the value of his holdings was around $4.47 million, dropping to $2.55 million by September, before spiking again to approximately $6.35 million by January 2024. This shows a dynamic approach to stock management and reflects both confidence in his leadership and awareness of market trends.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Madrigal Pharmaceuticals, Inc. CEOs

M

Alex G. Howarth

Ex-CEO of Madrigal Pharmaceuticals, Inc.

Sector of Economy

Healthcare

CEO of Madrigal Pharmaceuticals, Inc. for

7 years 7 months (Jul 2016 - Mar 2024)

Previous Experience

CFO of Madrigal Pharmaceuticals, Inc.

Rivals

Competitors/colleagues of Alex G. Howarth

Holdings

See how much did Alex G. Howarth make over time.

Alex Howarth's stock holdings in Madrigal Pharmaceuticals have shown significant volatility. Starting the year 2023 with about $4.47 million in stock value, he witnessed ups and downs, notably reaching a low of $2.55 million in September. However, by January 2024,...

Alex Howarth's stock holdings in Madrigal Pharmaceuticals have shown significant volatility. Starting the year 2023 with about $4.47 million in stock value, he witnessed ups and downs, notably reaching a low of $2.55 million in September. However, by January 2024, his holdings climbed back up to approximately $6.35 million. This reflects his active management of assets and responses to market changes, showcasing his financial acumen. Notably, the fluctuations indicate that Alex has strategically navigated through complex market conditions, indicating a hands-on approach to both his role as CEO and as a shareholder. His awareness of stock performance complements his role in leading the company's strategic direction.

Loading...

Insider Trading

See recent insider trades of Alex G. Howarth.

MDGL

4,803 shares

MDGL

Jan 23, 2024

Received

MDGL

15,001 shares

MDGL

Jan 16, 2023

Received

Compensation History

See how much did Alex G. Howarth make over time.

In 2023, Alex G. Howarth's total compensation was $1,668,000. This included a salary of $875,000, a performance-based bonus of $268,000, and a $520,000 sign-on bonus. The performance metrics used to calculate his bonuses were based on ambitious goals related to clinical research and corporate development, which he achieved at 122.5% of the target. This demonstrates not just his leadership competency but also his focus on aligning company goals with shareholder interests. Notably, Alex had no vested stock in 2023 due to the long-term vesting criteria of his stock options and awards, emphasizing that he is fully invested in the company's future success rather than short-term gains.

Year

2023

Total Compensation

$1.66M

Salary

$875.00K

Board Justification

The compensation philosophy is designed to align with strategic goals and stockholder interests, ensuring competitive compensation to attract and retain top talent while rewarding performance.

Bonus

$268.00K

Board Justification

The bonus is based on the achievement of performance objectives set at 122.5% of the target bonus amount for 2023.

Other

$520.00K

Board Justification

A one-time sign-on cash bonus of $520,000 was provided to Mr. Sibold upon his appointment as CEO.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was vested in 2023 as the RSUs and PSUs granted to Mr. Sibold are subject to time-based and performance-based vesting, respectively.

Performance Metrics

Performance metrics include clinical, research and development, commercial development, and finance objectives.

Other Madrigal Pharmaceuticals, Inc. CEOs

Here are other CEOs of Madrigal Pharmaceuticals, Inc.

Mardi C. Dier

CEO of Madrigal Pharmaceuticals, Inc.

March 2024 - Present